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Abstract
Multiple factors may contribute to the decision to initiate methylphenidate treatment in children such as maternal sociode-
mographic factors of which relatively little is known. The objective was to investigate the association between these factors 
and methylphenidate initiation. The study population included 4243 children from the Generation R Study in the Nether-
lands. Maternal sociodemographic characteristics were tested as determinants of methylphenidate initiation through a time-
dependent Cox regression analysis. Subsequently, we stratified by mother-reported ADHD symptoms (present in 4.2% of 
the study population). When ADHD symptoms were absent, we found that girls (adjusted HR 0.25, 95%CI 0.16–0.39) and 
children born to a mother with a non-western ethnicity (compared to Dutch-Caucasian) (adjusted HR 0.42, 95%CI 015–0.68) 
were less likely to receive methylphenidate. They were more likely to receive methylphenidate when their mother completed 
a low (adjusted HR 2.29, 95%CI 1.10–4.77) or secondary (adjusted HR 1.71, 95%CI 1.16–2.54) education. In conclusion, 
boys and children born to a mother of Dutch-Caucasian ethnicity were more likely to receive methylphenidate, irrespective 
of the presence of ADHD symptoms.
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Introduction
Worldwide, 5% of children will develop or have symptoms 
of attention deficit hyperactivity disorder (ADHD) [1]. Stim-
ulant medication is widely used for the treatment of ADHD 
of which methylphenidate is considered the first choice of 
pharmacological treatment [2]. However, not all children 
who are eligible for methylphenidate treatment receive the 
medication and conversely some children may receive meth-
ylphenidate when it is not needed [3]. When initiating treat-
ment with methylphenidate, the risk of potential negative 
outcomes (such as major depression and suicidal behavior) 
may also be considered as shown in previous studies [4, 
5]. Even though, there are clear guidelines with regard to 
ADHD treatment, symptom severity and functional impair-
ment are not the sole determinants of treatment initiation. 
Numerous studies have explored other factors that might 
contribute to the use of stimulant medication in children 
diagnosed with ADHD [6, 7]. One of the factors known to be 
related to initiation with stimulant medication is the patient’s 
sex. Stimulants are more often prescribed to boys than girls, 
which can partly be explained by the fact that ADHD is 
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more often diagnosed in boys than in girls. This may be 
reflected by the differences in ADHD symptoms between 
boys and girls [8–10]. Apart from child characteristics, the 
prescribing behavior of physicians as well as the availability 
of non-pharmacological treatment options to the family are 
important [11–13].
Not every child diagnosed with ADHD receives pharma-
cological treatment [14]. While symptom’s severity as well 
as non-response to non-pharmacological interventions play 
an important role in the initiation of pharmacological treat-
ment [14], there may be other factors contributing to a fami-
ly’s decision to visit a general practitioner or specialist (such 
as knowledge, apprehension regarding therapy and experi-
ence with the healthcare system), a child psychiatrist or to 
start medication [15, 16]. Children often rely on caregivers 
for support and management of chronic conditions involv-
ing taking medications [17]. Mothers are mostly considered 
as the primary caregiver, but the importance of maternal 
characteristics in determining methylphenidate treatment 
initiation should be studied further [18–20]. Previous stud-
ies showed that the utilization of ADHD medication may be 
influenced by sociodemographic factors such as ethnicity 
and socioeconomic status [9, 21]. These studies showed that 
medication was less frequently prescribed to ethnic minor-
ity groups. The relation between methylphenidate use and 
socioeconomic disadvantage could be associated with men-
tal health problems in general [9]. However, these studies do 
not address the presence or absence of any ADHD related 
symptoms in these children, which may vary across the 
different sociodemographic groups [22, 23]. Furthermore, 
many studies about ADHD treatment are conducted in the 
US and they have a different healthcare system compared 
to Europe [24, 25]. A previous study in the Netherlands 
found that factors on the individual, family and GP practice 
level may determine ADHD medication prescription. They 
hypothesized that child characteristics would have the largest 
impact, followed by family and GP practice characteristics 
[26]. However, family characteristics that were included in 
this study was only limited to the number of children per 
household and previous ADHD medication use within their 
family. Other factors such as household income, education 
and ethnicity were not considered, but may play a role in the 
decision to start therapy with methylphenidate.
The objective of our study was to investigate the associa-
tion between maternal sociodemographic and prenatal life-
style factors in relation to child methylphenidate treatment 
initiation. Subsequently, we performed analyses stratified by 
the presence of (mother reported) clinically relevant ADHD 
symptoms in children using the determinants that were sig-
nificantly associated with child methylphenidate prescrip-
tion. We hypothesized that maternal sociodemographic fac-
tors are associated with the initiation of methylphenidate 
treatment in children. These maternal factors would account 
for variance in the treatment initiation, beyond the individual 
child characteristics. Apart from gender and the indication, 
family factors may have a large impact on the decision to 
start therapy with methylphenidate.
Methods
Design and Study Population
The study was conducted within The Generation R Study, 
which is a large prospective population-based cohort study 
investigating children’s health from fetal life onwards in 
Rotterdam, the Netherlands [27]. Pregnant women who 
were resident in Rotterdam and who had a delivery date 
between April 2002 and January 2006 were asked to par-
ticipate in the study. In this cohort, detailed and extensive 
data collection has been conducted, which include question-
naires, interviews, and behavioral observations of children 
and their parents [27]. In addition, we retrieved pharmacy 
records from community pharmacies throughout Rotterdam, 
depending on where the child resided. In total, 9778 moth-
ers were enrolled in the study and gave birth to 9749 live 
born children (Fig. 1). Of this group, 7896 children and their 
parents were invited to participate in the follow-up study 
(56 died; 1086 withdrawn from study; 639 lost to follow-up 
(no response to the invitation to participate in the follow-up 
study or moved to another city outside the defined study 
area). Children were excluded from the study if their par-
ents chose to later withdraw from the study (n = 74). They 
were also excluded if no consent by their parents was pro-
vided (n = 1084) or because no consent was given by the 
pharmacist or the child could not be found in the pharmacy 
(n = 2567). Pharmacy records could be obtained from 4243 
children. The Medical Ethics Committee of the Erasmus 
Medical Center approved all study procedures, and parents 
provided written informed consent.
Child Methylphenidate Prescription
Pharmacy records of Generation R participants were col-
lected based on the living area of their mothers (northern, 
southern, western of eastern part of Rotterdam). This infor-
mation was used to determine at which pharmacies they may 
collect their medication. Pharmacists were contacted and 
asked for consent to retrieve the pharmacy records. Children 
may collect their medication at more than one pharmacy and 
these pharmacy records were all linked to one particular 
child. Pharmacy records of children may not be available 
because either their pharmacy or their parents did not give 
consent to retrieve these records or because the child’s phar-
macy could not be found.
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For 4243 individuals in The Generation R Study, all 
prescriptions which were filled at their pharmacy during 
the entire study period were gathered starting at birth. 
For each prescription we had the product name, anatomi-
cal therapeutic chemical (ATC) code [28], date of filling, 
number of delivered tablets/capsules, and prescribed daily 
number of doses. All study participants were followed 
from date of birth until a first prescription of methylphe-
nidate or end of the study period at 1 September 2017, 
whichever came first. Information about the use of ADHD 
medication (N06BA) was obtained from the collected 
pharmacy dispensing records. Furthermore, information 
about the type of prescriber of the first methylphenidate 
prescription (e.g. general practitioner, specialist or at the 
hospital) was available in the electronic pharmacy records.
Child ADHD Symptoms
The Child Behavior Checklist (CBCL/1.5–5 and 
CBCL/6–18) was used to obtain information about behav-
ioral and emotional problems in children [29]. The CBCL is 
a questionnaire that was filled out by mothers when children 
were 1.5, 3, 5 and 9 years of age. The CBCL/6–18 was only 
used at the 9 years assessment. Children were classified as 
having ADHD symptoms in the borderline clinical range, 
when the cut-off score was above the  93rd percentile [29, 
30]. For the statistical analysis, we used the last question-
naire that was filled out by the mother prior to date of first 
methylphenidate prescription. The average time between the 
completion of the last CBCL and first prescription of meth-
ylphenidate was 2.9 years (SD: 3.6).
Child and Maternal Characteristics
The following maternal lifestyle and demographic char-
acteristics were considered as potential determinants for 
starting treatment with methylphenidate: maternal age at 
intake, ethnicity (Dutch-Caucasian or other Western, non-
western, defined according to the classification of Statistics 
Netherlands [31]), household income (< €1200,  > €1200 
and < 2000, > €2000 per month), education level (primary, 
secondary, higher), marital status (married, living together, 
no partner), alcohol use (yes/no), caffeine intake (yes/no) 
and smoking during pregnancy (yes/no) [32]. Maternal 
psychopathology in mid-pregnancy was assessed, using the 
Brief Symptom Inventory (BSI). This is a validated self-
report questionnaire, which includes a spectrum of psychi-
atric symptoms. A weighted sum score above 0.75 means 
that clinically relevant psychopathology symptoms were pre-
sent [33, 34]. In addition, we considered the use of selective 
serotonin reuptake inhibitors (SSRIs) during pregnancy (the 
most frequently used antidepressant in our study), which 
was obtained from pharmacy records and self-reported infor-
mation [35]. This information from mothers was collected 
during pregnancy or at birth of their child. Finally, we also 
considered child’s sex as a potential determinant.
Analysis
Child and family characteristics were presented for all chil-
dren with pharmacy records, which also included the type of 
prescriber, age of first methylphenidate prescription and the 
life style factors of mothers. Second, we investigated which 
maternal lifestyle and demographic characteristics were 
related to methylphenidate initiation. For the main analyses, 
we calculated the hazard ratio (HR), with 95% confidence 
interval (CI) for each determinant associated with initiation 
of methylphenidate. We used a time-dependent Cox regres-
sion model, where non-methylphenidate users can serve as 
Adolescence period: 
7,968 children and 
their parents invited 
74 withdrawn  
Study populaon: 
4,243 children with 
pharmacy record data  
1,084 no consent 
parents (not received 
or signed) 
2,567 no consent 
from pharmacy or the 
child could not be 
found in the 
pharmacy 
6,810 children with 
parental consent   
7,894 children in the 
follow-up study  




639 lost to follow-up 
Fig. 1  Selection study population
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a control more than one time [36]. A time-dependent model 
was used, because the CBCL questionnaires were completed 
at different time points (1.5, 3, 5 and 9 years). For this analy-
sis, we considered the presence of clinically relevant ADHD 
symptoms based on the CBCL questionnaire data that was 
completed prior to the date of first methylphenidate pre-
scription. As determinants of methylphenidate treatment 
initiation, we considered all above-mentioned maternal and 
child characteristics in the univariate analysis. In addition, 
a multivariable Cox regression analysis was performed with 
the variables that were univariably associated. Separately, 
we tested the interaction between maternal education and 
ethnicity in the post-hoc analysis with an interaction term. 
Finally, we performed analyses stratified by clinically rele-
vant ADHD symptoms (above 93rd percentile) using factors 
that were associated with child methylphenidate prescription 
in the main analysis.
First, we performed complete-case analyses. In the non-
response analysis, we explored differences between mothers 
and children of responders and non-responders. In the sensi-
tivity analysis, we performed the same analysis using mul-
tiple imputation of the covariates (where less than 30% was 
missing) using the expectation maximization algorithm to 
deal with missing data. Results were considered statistically 
significant at p < 0.05. Statistical analyses were performed 




Pharmacy records were available for 4243 children. A 
total of 295 children were prescribed an ADHD medica-
tion, of whom 291 (99%) received methylphenidate. Due 
to the small number of children with other ADHD medi-
cation (dexamphetamine n = 3 and atomoxetine n = 1), we 
only analyzed data of children who started their treatment 
with methylphenidate. The average age of receiving the 
first methylphenidate prescription was 9.4 years. Of these 
children, 207 received their first methylphenidate prescrip-
tion from a specialist (71%) and they were more often boys 
(n = 221, 75.9%).
Demographic and Lifestyle Characteristics
In Table 1, the characteristics of the study population are 
shown. Half of the children who were included in our study 
were girls (n = 2066, 48.7%). Of all children whose mother 
filled in the CBCL questionnaires (n = 2070), 179 (8.6%) 
had ADHD symptoms above the cut off score. Furthermore, 
1621 (38.2%) mothers had a non-western background, 2016 
Table 1  Maternal and child characteristics of study population
Numbers are given in numbers (percentages) unless stated otherwise. 
The numbers of the missing values are not shown in this table, but 
are as follows: type prescriber 22 (0.5%); reported ADHD symptoms 
2173 (51.2%); ethnicity 142 (3.3%); household income 1086 (25.6%); 
maternal education 427 (10.1%); marital status 420 (9.9%); smok-
ing during pregnancy 591 (14%); alcohol use during pregnancy 930 
Characteristic N (%), n = 4243
Sex, girl 2066 (48.7)
ADHD symptoms present (CBCL by mother)a
 No 1891 (44.6)
 Yes 179 (4.2)




 No methylphenidate prescription 3955 (93.2)
 Specialist 209 (4.9)
 General practitioner 37 (0.9)
 Hospital 10 (0.2)
 Maternal age (at intake) in years, mean (SD) 30.6 (5.2)
Parity
 1 2260 (53.3)
 > 1 1983 (46.7)
Ethnicity mother
 Dutch-Caucasian and other western 2480 (58.4)
 Non-western 1621 (38.2)
Household income
 < €1200 570 (13.4)
 €1200–2000 571 (13.5)
 € > 2000 2016 (47.5)
Maternal education level
 No education/primary education 361 (8.5)
 Secondary education 1708 (40.3)
 Higher education 1747 (41.2)
Marital status
 Married 1921 (45.3)
 Living together 1418 (33.4)




Alcohol use during pregnancy
 No 1991 (46.9)
 Yes 1322 (31.2)




 < 0.76 2770 (65.3)
 0.76 and higher 485 (11.4)
SSRI use during pregnancy
 No 1798 (42.4)
 Yes 36 (0.8)
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(47.5%) had a relatively high monthly household income 
(€ > 2000) and only a small percentage had a low education 
level (n = 361, 8.5%).
Determinants of Methylphenidate Treatment 
Initiation
In the multivariable analysis (Table 2), we found that girls 
were less likely to receive methylphenidate compared to 
boys (adjusted HR 0.34, 95%CI 0.24–0.49). As expected, 
children were more likely to receive a methylphenidate pre-
scription when mothers reported clinically relevant child 
ADHD symptoms (adjusted HR 8.67, 95%CI 6.25–12.02). 
We observed that children were more likely to start treat-
ment with methylphenidate when mothers completed sec-
ondary school (adjusted HR 1.52, 95%CI 1.09–2.12) com-
pared to mothers with a higher education level. Furthermore, 
a non-western ethnicity of mothers was associated with a 
lower likelihood of methylphenidate treatment (adjusted HR 
0.41, 95%CI 0.28–0.60) compared to a Dutch-Caucasian or 
other western background. Finally, the interaction between 
maternal education and maternal ethnicity was found to be 
significant (P: 0.001). Children whose mother received a 
secondary education as compared to a higher education in 
the western group were more likely to receive methylpheni-
date (HR 1.93, 95%CI 1.45–2.58). In the non-western group, 
no significant association was found (no/ primary education 




Table 3 shows that girls without clinically relevant ADHD 
symptoms were less likely to receive a methylphenidate 
prescription compared to boys (adjusted HR 0.25, 95%CI 
0.16–0.39). Children with mothers of a non-western back-
ground were less likely to receive a methylphenidate pre-
scription compared to those with a Dutch-Caucasian back-
ground (adjusted HR 0.42, 95%CI 0.26–0.68). Furthermore, 
we found that children were more likely to receive a meth-
ylphenidate prescription when mothers completed a lower 
education compared to those who completed high educa-
tion (no education/ primary education adjusted HR 2.29, 
95%CI 1.10–4.77 and secondary education adjusted HR 
1.71, 95%CI 1.16–2.54).
Presence of ADHD Symptoms
When child ADHD symptoms above the cut-off were 
reported, we found that girls were less likely to receive a 
methylphenidate prescription than boys (adjusted HR 0.53, 
95%CI 0.32–0.90) (Table 3). Children of non-western moth-
ers were less likely to receive a methylphenidate prescription 
compared to children of mothers with a Dutch-Caucasian 
or other western background (adjusted HR 0.45, 95%CI 
0.26–0.77).
Sensitivity Analyses
In the multivariable analysis with imputed data we found 
similar results: direction and size of the effect estimates 
overall did not change much. We found that girls were less 
likely to receive methylphenidate (adjusted HR 0.31, 95%CI 
0.21–0.47) or when they had a mother with a non-western 
background (adjusted HR 0.48, 95%CI 0.31–0.75). Children 
were more likely to receive a methylphenidate prescription 
when they had ADHD symptoms above the cut-off reported 
by their mothers (adjusted HR 10.12, 95%CI 6.95–14.74). 
However, the association between methylphenidate initia-
tion and a low maternal education was non-significant (no/
primary education adjusted HR 2.01, 95%CI 0.94–4.28; 
secondary education adjusted HR 1.37, 95%CI 0.94–2.01).
Non‑response Analyses
For the variables that were included in the analyses, less 
than 30% were missing, except for SSRI use during preg-
nancy (56.8%) and the reported clinically relevant ADHD 
symptoms (51.2%). The non-response analysis showed no 
significant differences between children with and without 
information for the maternal characteristics. However, we 
found that 2173 women did not complete the CBCL ques-
tionnaires at all or did not complete the questionnaire prior 
to the first prescription of methylphenidate. A dropout analy-
sis on this variable showed that the missing of the CBCL 
questionnaire was not significantly associated with sex, but 
it was associated with ethnicity (P < 0.001), maternal educa-
tion (P < 0.001) and methylphenidate initiation (P < 0.001).
The analysis in the group without information on ADHD 
symptoms (missing information) showed similar results for 
sex (girls adjusted HR 0.49, 95%CI 0.30–0.83) and ethnic-
ity (non-western background adjusted HR 0.61, 95%CI 
(21.9%); caffeine intake during pregnancy 670 (15.8%); maternal 
psychopathology 988 (23.3%) and SSRI use during pregnancy 2409 
(56.8%)
* The information about the type of prescriber was only provided of 
children who received methylphenidate (n = 291)
a Clinically relevant ADHD symptoms: Children were classified 
as having ADHD symptoms in the borderline clinical range when 
their cut-off score was above the  93rd percentile. BSI Brief Symptom 
Inventory, N number of children, SD standard deviation, SSRI selec-
tive serotonin reuptake inhibitors. All numbers are given in percent-
ages or mean (SD)
Table 1  (continued)
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Table 2  Maternal and child 
factors associated with 
methylphenidate treatment 
initiation
A time-dependent model was used where the ADHD scores of the last completed CBCL questionnaire 
prior to methylphenidate prescription was considered. In the adjusted model we included all univariably 
associated determinants. The number of non-methylphenidate users are not presented in the table due to the 
time component of the model where non-methylphenidate users can serve as a control more than once
a Clinically relevant ADHD symptoms: Children were classified as having ADHD symptoms in the border-
line clinical range when their cut-off score was above the  93rd percentile ADHD indicates attention defi-
cit hyperactivity disorders, BSI Brief Symptom Inventory, CBCL Child Behavior Checklist, CI confidence 
interval, HR hazard ratio, N number of children, SD standard deviation, SSRI selective serotonin reuptake 
inhibitor
Characteristic Cases, N (%)
(n = 291)
Crude HR, 95%CI Adjusted HR, 95%CI
(cases, n = 180)
Sex child
 Boy 221 (75.9) Ref Ref
 Girl 70 (24.1) 0.31 (0.24–0.41) 0.34 (0.24–0.49)
ADHD symptoms present (CBCL by mother)a
 No 128 (44.0) Ref Ref
 Yes 78 (26.8) 9.06 (6.71–12.23) 8.67 (6.25–12.02)
Maternal age at baseline, years
 < 25 44 (15.1) Ref
 25–30 85 (29.2) 0.87 (0.59–1.27)
 31–36 123 (42.3) 0.77 (0.54–1.10)
 > 36 39 (13.4) 0.81 (0.52–1.27)
Parity
 1 154 (52.9) Ref
 > 1 137 (47.1) 1.02 (0.80–1.29)
Ethnicity mother
 Dutch-Caucasian and other western 201 (69.1) Ref Ref
 Non-western 82 (28.2) 0.60 (0.46–0.79) 0.41 (0.28–0.60)
Household income
 < €1200 29 (10.0) 0.67 (0.44–1.00)
 €1200–2000 38 (13.1) 0.89 (0.61–1.28)
 € > 2000 150 (51.5) Ref
Maternal education level
 No education/primary 20 (6.9) 0.91 (0.56–1.49) 1.04 (0.52–2.06)
 Secondary 138 (47.4) 1.37 (1.06–1.78) 1.52 (1.09–2.12)
 Higher 106 (36.4) Ref ref
Marital status
 Married 113 (38.8) Ref
 Living together 106 (36.4) 1.29 (0.98–1.70)
 No partner 40 (13.7) 1.44 (0.99–2.10)
Alcohol use during pregnancy
 No 124 (42.6) Ref
 Yes 100 (34.4) 1.23 (0.94–1.62)
Smoking during pregnancy
 No 196 (67.4) Ref Ref
 Yes 55 (18.9) 1.48 (1.09–2.03) 1.02 (0.70–1.48)
Caffeine intake during pregnancy
 No 143 (49.1) Ref
 Yes 97 (33.3) 1.04 (0.80–1.35)
Maternal psychopathology (BSI)
 < 0.76 178 (61.2) Ref
 0.76 and higher 33 (11.3) 1.06 (0.72–1.56)
SSRI use during pregnancy
 No 132 (45.4) Ref
 Yes 4 (1.4) 1.58 (0.55–4.53)
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0.36–1.03). For maternal education, we found that a lower 
education was significantly associated with a decreased risk 
of methylphenidate use compared to higher education (no 
education/ primary HR 0.31, 95%CI 0.11–0.91).
Pharmacy records were not available for half of the 
cohort participants (results not shown in table). For chil-
dren of whom no pharmacy records were available, we found 
that their mothers were significantly younger (maternal age 
29.6 vs 30.6, P < 0.001), had a lower household income 
(20.6% < 1200 vs 18.1%, P < 0.02), were lower educated 
(12.0% no education/primary education vs 9.5%, P < 0.001), 
more often did not have a partner (15.6% no partner vs 
12.7%, P0.001), used less alcohol during pregnancy (35.4% 
vs 39.9%, P < 0.001), smoked more during pregnancy 
(19.7% vs 16.3%, P < 0.001) and had a lower caffeine intake 
during pregnancy (61.9% vs 58.9%).
Discussion
Main Findings
In the current study, we found that several child and maternal 
sociodemographic factors were related to methylphenidate 
treatment initiation. In our study, we were able to examine 
these determinants stratified by the presence and absence 
of clinically relevant ADHD symptoms. Our findings show 
that methylphenidate was more frequently prescribed to 
boys than girls. It also shows that children of mothers with 
a non-western background were less likely to receive a 
methylphenidate treatment than children of mothers with a 
Dutch-Caucasian or other western background. These find-
ings are both in line with results that have been shown in 
previous studies [9, 10, 37]. However, the previous studies 
only addressed the association with sociodemographic fac-
tors in patients with an ADHD diagnosis. In our study, we 
found that even when no ADHD symptoms were reported by 
mothers, boys and children born to mothers with a western 
ethnic background were still more likely to receive methyl-
phenidate. Furthermore, we found that a low and second-
ary maternal education (compared to a high education) was 
associated with methylphenidate prescription in children 
without reported symptoms. A previous study of Russel 
et al., found no significant association between maternal 
education and medication use in children in a UK popula-
tion [8]. This could also be explained by the differences in 
the educational system of the Netherlands and the UK. It is 
also possible that they did not find the association as they 
only explored the sociodemographic factors of medication 
use among children with ADHD.
Explanations for These Findings
First, sex differences with regard to use of methylphenidate 
or other stimulants is probably related to the diagnosis of 
ADHD, which is more common in boys than girls [38]. 
This could be explained by the fact that ADHD was once 
thought to be a predominantly male disorder [39]. Boys with 
Table 3  Maternal and child factors associated with methylphenidate treatment initiation stratified by the presence and absence of clinically rel-
evant ADHD symptoms
A time-dependent model was used where the ADHD scores of the last completed CBCL questionnaire prior to methylphenidate prescription was 
considered. In the adjusted model we included all determinants. The number of non-methylphenidate users are not presented in the table due to 
the time component of the model where non-methylphenidate users can serve as a control more than one time
a Clinically relevant ADHD symptoms: Children were classified as having ADHD symptoms in the borderline clinical range when their cut-off 
score was above the 93rd percentile
b Corrected for time between completion of CBCL and first methylphenidate prescription. ADHD indicates attention-deficit hyperactivity disor-
der; CBCL child behavior checklist, CI confidence interval, HR hazard ratio, N number of children
Characteristic Cases, N Crude HR, 95% CI Adjusted HR, 95%  CIb Crude HR, 95% CI Adjusted HR, 95%  CIb
ADHD symptoms absent ADHD symptoms  presenta
Sex
 Boy 159 Ref Ref Ref Ref




149 Ref Ref Ref Ref
 Non-western 55 0.51 (0.33–0.77) 0.42 (0.26–0.68) 0.41 (0.25–0.68) 0.45 (0.26–0.77)
Maternal education
 No education/primary 16 1.20 (0.61–2.35) 2.29 (1.10–4.77) 0.38 (0.14–1.03) 0.60 (0.21–1.70)
 Secondary 101 1.33 (0.90–1.95) 1.71 (1.16–2.54) 0.92 (0.55–1.54) 1.10 (0.65–1.86)
 Higher 74 Ref Ref Ref Ref
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clinically ADHD, present more outwardly signs of ADHD, 
such as hyperactive and impulsive behavior, while girls pre-
sent more inwardly signs, such as inattentiveness and low 
self-esteem (attention deficit disorder, ADD)[40–42]. This 
may both lead to boys being diagnosed with ADHD more 
often as well as earlier initiation of pharmacological treat-
ment as shown previously [8]. However, in our study we 
observed that girls are still less likely to receive methylphe-
nidate irrespective of the presence of ADHD symptoms. It 
is possible that girls may be less qualified as their symptoms 
are not considered severe enough [43]. Parents may find it 
more difficult to cope with the hyperactive and impulsive 
behavior, which is more prevalent in boys and are there-
fore more likely to seek help by visiting the GP. This could 
also be the reason why boys are more likely to be diagnosed 
and treated with medication. It could imply that girls with 
ADHD symptoms are undertreated while on the other hand 
boys without ADHD may be overtreated [44]. It has also 
been noted that treatment programs are mainly focused on 
behavior management, which has a higher priority among 
boys than girls [45]. The difference in the symptom profile 
among boys and girls may be a reason why boys are more 
frequently prescribed methylphenidate than girls [46].
Second, we showed that children without ADHD symp-
toms of mothers who only had limited education (no educa-
tion, primary and secondary education) were more likely to 
receive a methylphenidate prescription. On the other hand, 
no significant association with maternal education was 
observed in children with ADHD symptoms. This finding 
might be interpreted that as long as the child has ADHD, 
there is no problem with inequity. When it comes to children 
without a diagnosis, there is inequity in treatment. How-
ever, these results should be carefully interpreted due to the 
association of missing information of ADHD symptoms and 
maternal education. Nevertheless, a previously published 
study showed that a low maternal education was associated 
with less involvement in the decision-making of medication 
initiation in children. Parents may not have sufficient knowl-
edge about ADHD and feel that it is necessary to initiate 
methylphenidate when this is not thoroughly discussed with 
them [47]. Furthermore, we found that children of moth-
ers with a western ethnic background who received a lower 
education, were more likely to receive methylphenidate than 
children whose mother received a high education. It may 
seem that only mothers with a western ethnic background 
with a low education are less likely to be involved. This 
association was not found in the non-western group. This 
may suggest that mothers with a non-western background, 
irrespective of educational level, are treated differently than 
mothers with a western ethnic background.
Third, children with ADHD problems and parents from 
ethnic minority groups may have less access to healthcare 
or less communication with healthcare professionals due to 
a language barrier [23, 24, 48–51]. They may also receive 
less appropriate diagnoses or treatments as the symptoms 
observed for these disorders may differ across ethnic groups, 
and may differ from what clinicians are trained to expect 
[52, 53]. ADHD problems are also often recognized by 
teachers when children are more hyperactive than others. 
However, not all parents may consider hyperactivity as a 
behavioral problem as some parents may have a positive 
attitude towards a child with high energy [54]. This view 
and recognition of ADHD related problems may vary across 
different ethnic groups. Furthermore, ethnic minority fami-
lies may also be less likely to recommend medication and 
may prefer behavioral therapy over stimulant medication as 
found in previous studies [55, 56]. The findings of the cur-
rent study may reflect cultural differences, knowledge and 
perceptions about ADHD and its pharmacological treatment. 
These cultural differences may include behavioral expecta-
tions and tolerance, attachment, attention, personality and 
many other aspects of parenting. It does not only influences 
the environment in which a child with ADHD functions, 
but also in the way this child is understood and treated by 
its parents [57]. It may also influence the decision to visit 
a GP or not as some parents may not recognize emotional 
and behavioral problems as such. A previous study showed 
that significantly higher scores of hyperactivity were given 
in China and Indonesia compared to other countries such as 
the US [57]. However, it is also possible that parents pre-
fer to seek for other ways to cope with the hyperactivity or 
emotional problems of their child as they do not want to put 
their child on chronic medication.
These characteristics may be associated with certain 
medication types [58, 59, 60]. However, we have tested 
this with other medications such as SSRIs, antihistamines 
and NSAIDs. We found that children born to a mother 
with a non-western background or a low education were 
more likely to receive these medications (see supplemental 
Table 1). As prescribing of methylphenidate was less likely 
in girls and the non-western group, as can be seen in Table 3, 
this suggests that symptoms of these children may less read-
ily considered as a problem.
Strengths and Limitations
Strengths of our study are the relatively large population-
based cohort, its prospective design, independent registration 
of dispensed medicines, and the multi-ethnic nature of the 
sample which limit the chance of selection and information 
bias. Treatment initiation was based on pharmacy dispensing 
records, which is more accurate in terms of dispensation date 
than information on prescription medication from medical 
records or questionnaires as medication can be prescribed 
but not collected at pharmacies. However, our study also has 
some limitations. One of the limitations is that we had to rely 
Child Psychiatry & Human Development 
1 3
on questionnaires filled out by mothers to assess the pres-
ence of ADHD symptoms. These mother reports are consid-
ered valuable as they provide more insight into the perspec-
tive of the mothers with regard to their child’s behavior as 
ADHD symptoms are not always recognized as such across 
different demographic groups. However, not all mothers 
completed the CBCL questionnaire, which is also considered 
as an important limitation as we were not able to assess the 
presence of ADHD symptoms in these groups. Information 
bias may have occurred if the association between maternal 
characteristics or sociodemographic factors and treatment 
initiation is different for responders and non-responders, 
but this is difficult to ascertain. Nevertheless, the stratified 
analysis in the group without information on ADHD symp-
toms showed similar results for sex and ethnicity, except 
for maternal education. Further research is needed to assess 
the role of maternal education in the treatment initiation of 
methylphenidate, in particular in relation to the presence 
of ADHD symptoms. Another limitation is that pharmacy 
records were not available for half of the participants of The 
Generation R study as not all pharmacists provided consent 
to obtain the dispensing records from their pharmacies. As 
shown in the results, we found that mothers of children with-
out pharmacy records differed on several aspects. Despite 
this selection bias, we observed similar results in our study 
compared to the available literature showing an association 
between initiation of methylphenidate and ethnicity, mater-
nal education level and smoking during pregnancy [47, 61]. 
Furthermore, no information about other treatments (e.g. 
behavioral therapy) was available. Therefore, we were not 
able to assess if specific demographic groups were receiving 
behavioral therapy or no therapy at all. Finally, information 
about maternal characteristics were not available for each 
child, but the non-response analysis showed no significant 
differences between both groups.
Summary
We assessed the association between child and maternal 
factors and the initiation of methylphenidate treatment. 
Additionally, we also assessed the association in the strati-
fied analysis with mother-reported ADHD symptoms. The 
results of the study showed that apart from the child’s sex, 
the mother also plays an important role in the treatment ini-
tiation. We also found that even when no ADHD symptoms 
were reported, boys and children born to a mother of Dutch-
Caucasian ethnicity or a low maternal education were still 
more likely to receive methylphenidate treatment. The differ-
ence in symptom profile among boys and girls may affect the 
decision to start pharmacological treatment. Furthermore, 
the decision of parents to start treatment with methylpheni-
date may depend on their knowledge and perceptions about 
ADHD and pharmacological treatment, which may vary 
among different ethnic groups. Considering these findings, 
it is important for healthcare professionals to be aware of 
these differences and take these into account when decid-
ing on initiating treatment with methylphenidate. As par-
ents play an important role, they should always be involved 
in the decision-making process of treatment initiation with 
methylphenidate. Reasons for treatment initiation in children 
without ADHD symptoms should be further investigated.
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